about
Valproic acid and fatalities in children: a review of individual case safety reports in VigiBaseA proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid.Topiramate enhances the risk of valproate-associated side effects in three children.Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.Delayed-onset neutropenia with divalproex sodium.Valproate-associated coagulopathies in children during short-term treatment.A case of thrombocytopenia associated with valproic Acid treatment.Anticonvulsant drugs and hematological disease.Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the LiteratureRisk of aplastic anemia in patients using antiepileptic drugs.Cerebral palsy and anaesthesia.Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in miceScreening electroencephalograms in autism spectrum disorders: evidence-based guideline.Management of bleeding emergencies: when to use recombinant activated factor VII.Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy.Brain tumors and epilepsy.Considerations in perioperative assessment of valproic acid coagulopathy.Treatment of epilepsies associated with typical absences.Seizures in low- and high-grade gliomas: current management and future outlook.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.The long-term safety of antiepileptic drugs.Psychotropic drugs and their impact on the treatment of paediatric dental patients.Psychiatric and psychosocial challenges in patients undergoing haematopoietic stem cell transplants.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients.Valproate-associated reversible encephalopathy in a 3-year-old girl with Pallister-Killian syndrome.Divalproex sodium in severe anaemia: a case report.Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report.Massive scalp hematoma: An unusual presentation of valproic acid toxicity.Do structural properties explain the anticonvulsant activity of valproate metabolites? A QSAR analysis.Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents.Dental care in patients with epilepsy: a survey of 82 patients and their attending dentists and neurologists in southern Germany.Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.A severe valproate overdose with complete recovery in a newborn.Antiepileptic drugs: Role in paediatric poisoning.Megakaryocyte lineage development is controlled by modulation of protein acetylation.Thrombocytopenia and Cornelia de Lange syndrome: Still an enigma?A review of valproate in psychiatric practice
P2860
Q28543695-1F8F5681-AE34-4F79-83B4-5C9B3C45EA56Q33267359-EBDD86DE-7418-482D-9580-C96141B8619AQ33341608-4776AADD-D8CC-4DF2-A591-379D8F4F621BQ33341929-E372CB18-DDBD-4052-821A-B3B0FCC26B78Q33376659-4F291CA9-5BEE-403C-A924-B1A5C9F1BF48Q33380735-9899D83F-C712-4E93-8D3B-852CFCC76FF0Q33384723-1074A60B-A96A-4BE9-AF77-A2714FD9E7B9Q33412482-5792C831-FE95-4B22-B0E2-07CE2E68C07FQ33413868-78B44065-55FA-458E-B553-9A9352DBEBCAQ33436238-8ECE29FE-47BF-46EE-A398-FC993F0F9EBCQ34553959-384A5C0C-9FDC-44F1-868D-9A596766610CQ34619631-BA659F3F-30FD-4D0D-BC3C-9C029B162019Q35187043-84F9138E-BD13-4AF0-857B-1FC9B6049DAEQ36099191-2F27BBA4-CCEB-4A9B-9EF1-154146FCC6EDQ36349585-479C5A85-E1B7-4955-85E4-AFA635C526C2Q36917807-143CEC50-1CA0-4EB5-A0F4-9BC0F5C3CFB0Q37174060-6C9E86FA-D0C5-40C3-AFF5-E04E30FAE6A9Q37589946-CD8557A7-B070-41D5-B315-1B58435E042CQ37610185-F0381585-DD9F-474F-847F-4FAE0F734EC0Q37752365-06D35880-3D6F-4D6D-931A-73FB89F7F0B8Q38016227-C6252F39-FFE0-4241-8D50-435B60C2C158Q38106856-7C4DA8CD-B440-4630-80D0-F806E81CC33EQ38116482-23F2158B-E6AC-4F34-8B86-EE905E70BC91Q38203303-68F6D508-7986-4B36-90E7-EABA995A2C32Q38242979-2BC7C151-1125-40D0-83BC-AC5F3CD74E88Q38464083-7B6D07C3-6C23-4BE3-8070-62416247420FQ39257753-143E8113-D13A-4120-B353-75749A437C3CQ41360043-FFA10CD6-DB94-40BD-AB1B-E671CE0787E1Q42413374-F734C677-CE9D-429F-AD38-51E5C50FA6FDQ42429049-46CB36A9-AF32-4832-9EA0-2889081E13ADQ42794215-D8CB1D99-12B8-4CA7-A960-7945C2967406Q44004462-97C8A9FF-1AFD-4DAB-901B-EBB1577955B2Q46032928-EFB53B25-A3B0-49B0-9877-61A40134A32DQ47392357-39EE4237-7173-4D50-BE4C-E38B21F0CDD4Q48469935-909C5055-B268-472B-8EA7-269CBDE51B73Q48605718-157297C9-16A0-4DD9-A535-4043530BEC5AQ50424163-4F4F3D85-3F7A-4B90-99C6-03827A299E0FQ52716487-FC93DFDB-021A-48DA-A7CD-270E8C2223ABQ53502452-AEF4E8B2-2AE7-4661-BE9B-9C5264C5028AQ56093713-E731A6AF-3CA8-4A55-A104-14415837D12F
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Hematologic toxicity of sodium valproate.
@ast
Hematologic toxicity of sodium valproate.
@en
Hematologic toxicity of sodium valproate.
@nl
type
label
Hematologic toxicity of sodium valproate.
@ast
Hematologic toxicity of sodium valproate.
@en
Hematologic toxicity of sodium valproate.
@nl
prefLabel
Hematologic toxicity of sodium valproate.
@ast
Hematologic toxicity of sodium valproate.
@en
Hematologic toxicity of sodium valproate.
@nl
P1476
Hematologic toxicity of sodium valproate.
@en
P2093
P356
10.1097/00043426-200001000-00012
P577
2000-01-01T00:00:00Z